With Olon investing significantly in its production capacity and technical capabilities, CEO Paolo Tubertini believes the API specialist is well-positioned to provide resilience within the European supply chain. However, the chief executive also told Generics Bulletin that this robustness needs to be valued by pricing mechanisms.

Fresh from being named as the new president of Medicines for Europe, Medichem CEO Elisabeth Stampa sets out the association’s priorities around investment in European manufacturing, as well as identifying key obstacles that must be overcome to create a sustainable environment for off-patent medicines, in an exclusive interview with Generics Bulletin.

Ahead of the Global Generics & Biosimilars Awards, which are this year being held on Wednesday 25 October at the Hotel Porta Fira in Barcelona, we reveal our final shortlist of entrants across all 14 categories.